SCD Genotype Guide: Understanding All 9 Sickle Cell Genotypes

Why Genotype Matters

Sickle cell disease is not a single condition but a family of related hemoglobin disorders. The specific genotype — the combination of hemoglobin variants a person inherits — determines disease severity, clinical course, treatment approach, and prognosis. Accurate genotyping is essential for clinical management and patient counseling. Tracka captures and tracks genotype data for every registered patient to support personalized care pathways.

HbSS — Sickle Cell Anemia (Most Severe)

HbSS, commonly called sickle cell anemia, is the most severe and most common form of SCD. Patients inherit two copies of the hemoglobin S gene (one from each parent). Virtually all hemoglobin produced is HbS, with variable amounts of fetal hemoglobin (HbF). HbSS accounts for approximately 60 to 70% of all SCD cases globally.

Clinical features include severe chronic hemolytic anemia (hemoglobin typically 6 to 9 g/dL), frequent and severe pain crises, high risk of stroke (particularly in children), acute chest syndrome, splenic sequestration in early childhood, progressive organ damage, and reduced life expectancy compared to other genotypes. HbSS patients generally require the most intensive management, including hydroxyurea therapy, regular monitoring, and often chronic transfusion programs.

HbSC — Sickle-Hemoglobin C Disease (Milder)

HbSC results from inheriting one hemoglobin S gene and one hemoglobin C gene. It is the second most common SCD genotype, particularly prevalent in West Africa where HbC is common (highest in Burkina Faso, northern Ghana, and parts of Nigeria).

HbSC is generally a milder disease than HbSS, with higher baseline hemoglobin levels (typically 9 to 12 g/dL), less frequent pain crises, and better overall survival. However, HbSC patients are at particular risk for proliferative retinopathy (which can cause blindness), avascular necrosis of the femoral head, and complications during pregnancy. The milder phenotype can lead to delayed diagnosis, which is why universal screening is important.

HbSB+ Thalassemia — Sickle Beta-Plus Thalassemia (Variable)

HbSB+ thalassemia occurs when a person inherits one HbS gene and one beta-plus thalassemia gene. The beta-plus mutation allows reduced but not absent production of normal beta-globin, meaning these patients produce some hemoglobin A (HbA) alongside HbS. The amount of HbA produced varies and directly correlates with disease severity.

When HbA levels are relatively high (20 to 30%), the clinical picture is mild and similar to sickle cell trait. When HbA levels are low (5 to 15%), the disease can approach HbSS in severity. Careful hemoglobin analysis by HPLC or electrophoresis is essential for distinguishing HbSB+ from HbSS, as treatment intensity varies accordingly.

HbSB0 Thalassemia — Sickle Beta-Zero Thalassemia (Severe)

HbSB0 thalassemia results from inheriting one HbS gene and one beta-zero thalassemia gene. Because beta-zero mutations completely abolish normal beta-globin production, no HbA is produced. The clinical severity is essentially identical to HbSS, with similarly severe anemia, frequent crises, and high complication rates.

On standard hemoglobin analysis, HbSB0 can be indistinguishable from HbSS because both show absence of HbA. Family studies, genetic testing, or the presence of microcytosis (low MCV) can help differentiate the two. Treatment recommendations for HbSB0 are the same as for HbSS, including hydroxyurea initiation from 9 months of age.

HbSD — Sickle-Hemoglobin D Disease (Rare)

HbSD Punjab (or HbSD Los Angeles) results from co-inheritance of HbS with hemoglobin D. This is a relatively rare genotype found occasionally in individuals of Indian, Middle Eastern, or African descent. Clinical severity is moderate, with patients experiencing mild to moderate hemolytic anemia and occasional pain crises. The severity tends to be less than HbSS but more significant than sickle cell trait.

HbSE — Sickle-Hemoglobin E Disease (Rare)

HbSE combines hemoglobin S with hemoglobin E, which is most common in Southeast Asian populations. This is rare in Africa but can occur in areas with diverse populations. Clinical severity is generally mild, with mild anemia and infrequent crises, though splenomegaly and target cells on blood smear are common findings.

HbSO — Sickle-Hemoglobin O-Arab Disease (Rare)

HbSO Arab is a rare compound heterozygous state combining HbS with hemoglobin O-Arab. Despite its rarity, it is clinically significant because hemoglobin O-Arab enhances the polymerization of HbS, making HbSO Arab a moderately severe disease — more severe than might be expected from a rare variant. Patients may require management approaches similar to HbSS.

HbAS — Sickle Cell Trait (Carrier Status)

Individuals with HbAS carry one normal hemoglobin gene (HbA) and one sickle hemoglobin gene (HbS). They are carriers of the sickle cell trait but do not have sickle cell disease. HbA comprises roughly 55 to 60% of their total hemoglobin, with HbS at 35 to 40%. This ratio ensures adequate oxygen-carrying capacity and prevents sickling under normal physiological conditions.

Sickle cell trait is generally considered a benign condition. Carriers have normal life expectancy, normal hemoglobin levels, and no chronic symptoms. However, under extreme conditions — severe dehydration, high altitude, intense physical exertion — rare complications including exertional rhabdomyolysis and renal medullary carcinoma have been reported. The primary clinical importance of HbAS is genetic: two carriers have a 25% chance of having a child with HbSS disease with each pregnancy.

HbAA — Normal Hemoglobin

HbAA indicates the inheritance of two normal beta-globin genes. This is the most common hemoglobin genotype worldwide. Individuals with HbAA produce only normal hemoglobin A and have no risk of sickle cell disease or trait. However, in genetic counseling contexts, confirming HbAA status in a partner is important for assessing the risk to future offspring when the other partner is a known carrier or affected individual.

Severity Comparison and Clinical Implications

Genotypes can be broadly grouped by clinical severity for treatment planning purposes. Severe genotypes (HbSS, HbSB0, and HbSO Arab) require aggressive management with hydroxyurea, regular monitoring, and often chronic transfusion programs. Moderate genotypes (HbSC, HbSD) require regular clinical follow-up with attention to specific complications. Mild genotypes (HbSB+ with high HbA, HbSE) need monitoring but less intensive intervention. Carrier status (HbAS) requires genetic counseling but no disease-specific treatment.

Tracka supports genotype-specific care pathways, enabling healthcare programs to automatically tailor monitoring schedules, laboratory panels, and treatment protocols based on each patient's confirmed genotype. This ensures that the most severely affected patients receive the most intensive follow-up while optimizing resource allocation across the entire patient population.